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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.013Both Duchenne and golden retriever muscular dystrophy (GRMD) are caused by dystrophin deﬁciency.
The Duchenne muscular dystrophy sartorius muscle and orthologous GRMD cranial sartorius (CS) are
relatively spared/hypertrophied. We completed hierarchical clustering studies to deﬁne molecular
mechanisms contributing to this differential involvement and their role in the GRMD phenotype. GRMD
dogs with larger CS muscles had more severe deﬁcits, suggesting that selective hypertrophy could be
detrimental. Serial biopsies from the hypertrophied CS and other atrophied muscles were studied in
a subset of these dogs. Myostatin showed an age-dependent decrease and an inverse correlation with
the degree of GRMD CS hypertrophy. Regulators of myostatin at the protein (AKT1) and miRNA (miR-539
and miR-208b targeting myostatin mRNA) levels were altered in GRMD CS, consistent with down-
regulation of myostatin signaling, CS hypertrophy, and functional rescue of this muscle. mRNA and
proteomic proﬁling was used to identify additional candidate genes associated with CS hypertrophy.
The top-ranked network included a-dystroglycan and like-acetylglucosaminyltransferase. Proteomics
demonstrated increases in myotrophin and spectrin that could promote hypertrophy and cytoskeletal
stability, respectively. Our results suggest that multiple pathways, including decreased myostatin and
up-regulated miRNAs, a-dystroglycan/like-acetylglucosaminyltransferase, spectrin, and myotrophin,
contribute to hypertrophy and functional sparing of the CS. These data also underscore the muscle-
speciﬁc responses to dystrophin deﬁciency and the potential deleterious effects of differential muscle
involvement. (Am J Pathol 2013, 183: 1411e1424; http://dx.doi.org/10.1016/j.ajpath.2013.07.013)Duchenne muscular dystrophy (DMD) is an X-linked
recessive disorder caused by mutations in the dystrophin
gene and occurs in approximately 1 in 3500 live male
births.1 DMD boys show signs of skeletal muscle weakness,
evidenced by a delay in walking until approximately 18fellowship from the American
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.months and loss of ambulation by the teenage years. Necrotic
muscle ultimately fails to regenerate and is replaced with
ﬁbrous connective tissue and fat. Molecular and cellular
mechanisms underlying gradual muscle deterioration are
poorly understood.Establishment of the National Center for Canine Models of Duchenne
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Nghiem et alAnimal models of DMD include the mdx mouse and
golden retriever muscular dystrophy (GRMD) dog.2,3 De-
spite sharing the same fundamental genetic and biochemical
lesions, remarkable phenotypic variation occurs among
dystrophin-deﬁcient individuals and muscles. Mdx mice
have a relatively mild phenotype,4 whereas affected dogs
have clinical and pathological features consistent with those
of DMD.5 Even among DMD patients, who all lack dys-
trophin except for rare revertant ﬁbers, symptoms can vary
markedly.6 Dogs with GRMD also demonstrate pronounced
phenotypic variation, as some dogs lose the ability to walk
within the ﬁrst 6 months of life, whereas others remain
ambulatory to 10 years of age or older.7e9
In GRMD neonatal dogs, ﬂexor muscles such as the
sartorius are generally more severely involved than exten-
sors, potentially due to their role in crawling.10,11 Early
dystrophic histopathological changes seen in these diseased
muscles include myoﬁber necrosis evidenced by hyaline
ﬁbers, mineralization, edema, and inﬂammation, with asso-
ciated regeneration.10 Presumably, as dogs subsequently
begin to walk, weight-bearing extensor muscles such as the
vastus lateralis (VL) are more predisposed to injury and
display these same acute dystrophic changes. With regard to
individual muscle variation in DMD, extensors that undergo
eccentric contraction (eg, quadriceps femoris) are particularly
vulnerable to early weakness and wasting.12 On the other
hand, the extraocular muscles are largely spared.13
In DMD patients, most muscles atrophy over time, but
some, such as the gastrocnemius, undergo gross enlarge-
ment.14 On the basis of early histological studies of dys-
trophic muscle biopsies, this calf hypertrophy was initially
attributed to deposition of fat and ﬁbrotic tissue and was
termed pseudohypertrophy.15 However, in a series of 350
neuromuscular patients, including 9 with Becker muscular
dystrophy, quantitative ultrasound demonstrated that calf
hypertrophy was most often due to an actual increase in
contractile tissue.16 Mdx mice17 and dystrophin-deﬁcient
cats18 also have muscle hypertrophy in the absence of sig-
niﬁcant fat and connective tissue inﬁltration. The sartorius
muscle is particularly intriguing in both DMD and GRMD.
Humans have a single muscle, whereas dogs have cranial
and caudal bellies. Serving principally as a hip ﬂexor, the
sartorius extends from the pelvis to the proximal tibia in
people. Both heads of the canine sartorius also arise from
the pelvis, but they insert at different sites (caudal, proximal
tibia; cranial, distal femur). The cranial sartorius (CS)
muscle of neonatal GRMD dogs sustains extensive necro-
sis19 and then regenerates, often undergoing dramatic true
hypertrophy.9,20 In DMD patients, the sartorius muscle is
relatively spared and may hypertrophy late in the disease
process.21,22
Studies showing variable phenotypes among dystrophin-
deﬁcient species, individuals, and muscles suggest that
factors other than dystrophin deﬁciency, so-called second-
ary effects, are involved in the disease process.23 Deter-
mining the molecular underpinnings of the variable clinical1412and histopathological response to dystrophin deﬁciency
should provide insight into disease pathogenesis and
an opportunity to identify potential targets for therapy.
Phenotypicemolecular correlations are inherently limited in
DMD patients due to unavoidable restrictions of muscle
sampling. Animal studies are potentially more powerful
because multiple muscles can be sampled at different ages,
thus allowing clearer distinction of factors contributing to
disease progression. We chose to use the GRMD model of
DMD for this study because of the availability of archived
biopsy samples of multiple muscles from affected dogs at
two ages and corresponding systematic functional data that
could be correlated with mRNA and protein expression
ﬁndings.
Hierarchical clustering of several phenotypic markers,
including CS muscle size, tibiotarsal joint angle,7 and ﬂexor
and extensor torque,8 was ﬁrst performed in a group of
GRMD and normal dogs. Consistent with our prior studies,9
severely affected dogs tended to have larger CS muscles. To
achieve a better understanding of the molecular signals that
drive muscle hypertrophy, we extended a prior, largely
pathological study of differential muscle involvement in the
GRMD model.19 Proteins that are well known to inﬂuence
muscle size [myostatin (MSTN)]24,25 or potentially com-
pensate for dystrophin deﬁciency [utrophin (UTRN)]26 were
assessed in a subset of the dogs evaluated by hierarchical
clustering. MSTN showed an age-dependent decrease and
an inverse correlation with the degree of CS hypertrophy.
Regulators of MSTN at the protein (AKT1) and miRNA
(miR-539 and miR-208b targeting myostatin mRNA) level
were altered, consistent with down-regulation of MSTN
signaling, CS hypertrophy, and functional rescue of this
muscle. The growth factor myotrophin (MTPN) was in-
creased in the CS. These studies were augmented by anal-
ysis of mRNA, miRNA, and proteomic proﬁles from several
GRMD muscles at two different ages to elucidate additional
hypertrophic pathways. Although UTRN was also uni-
formly increased in GRMD muscles, there was no associ-
ation with CS size. Other membrane-associated proteins,
including a-dystroglycan, like-acetylglucosaminyltransferase
(LARGE), and b-spectrin, were increased in the GRMD CS,
consistent with a role in membrane stabilization. These results
indicate that several muscle proteins may act together to
stabilize myoﬁbers and promote muscle growth. Our ﬁndings
also further substantiate that differential muscle involvement
can exaggerate the GRMD phenotype. This suggests that
care should be taken with treatments targeting speciﬁc path-
ways, such asMSTN, that could selectively exaggeratemuscle
hypertrophy.
Materials and Methods
Overall Experimental Approach
Two different data sets were collected. Functional infor-
mation (Figure 1) was analyzed on a cohort of GRMDajp.amjpathol.org - The American Journal of Pathology
Figure 1 A schematic diagram of the canine pelvic limb that demon-
strates functional outcome measures in golden retriever muscular
dystrophy. The cranial sartorius (CS; line of diamonds) muscle is a hip
ﬂexor; the long digital extensor (dashed line) muscle is a tarsal joint
ﬂexor; the VL (dotted line) muscle is a stiﬂe extensor. As CS circumference
and tarsal joint ﬂexor strength increase and tibiotarsal joint angle and
extensor torque decrease, overall phenotype becomes more severe (see
Figure 2). This study focused on the endpoint of CS circumference
(hypertrophy).
Muscle Hypertrophy Dystrophy(n Z 49) and normal (n Z 4) dogs at 6 months of age,
creating a heat map that draws associations among a set of
functional endpoints. From the dogs included in the heat
map, we selected eight GRMD dogs with variable pheno-
types, as well as the four normal dogs, for further analysis.
Histopathological lesions and myoﬁber diameter, molecular
signatures [mRNA, microarray proﬁling, and quantitative
real-time PCR (qPCR)], and protein expression patterns
(proteomic proﬁling, Western blot analysis, and immuno-
ﬂuorescence microscopy) were assessed in archived samples
from three different muscles at both 4 to 9 weeks and 6
months of age. (A ﬂowchart of the experimental design is
shown in Supplemental Figure S1.) Four dogs used for
mRNA proﬁling and ﬁve other age-matched phenotyped
dogs, but not mRNA proﬁled, were studied at the miRNA
level. An additional six GRMD dogs from the heat map
were analyzed by light microscopy for myoﬁber measure-
ment at 4 to 9 weeks and by qPCR at 6 months of age to
further conﬁrm the MSTN mRNA ﬁndings.
Animals
All dogs were used and cared for according to principles
outlined in theNational Institutes of HealthGuide for the Care
and Use of Laboratory Animals. Dogs were housed at the
Kornegay laboratory either at the University of Missourie
Columbia or University of North Carolina at Chapel Hill.
GRMDdogswere identiﬁed at 1 day of age based on dramatic
elevation of serum creatine kinase (CK) levels.5 Genotype
was conﬁrmed by PCR when CK results were ambiguous.
Characteristic clinical signs subsequently developed.
Functional Outcome Measures
The phenotypic variables assessed in these dogs included CS
muscle circumference, tibiotarsal joint angle, and tibiotarsalThe American Journal of Pathology - ajp.amjpathol.orgjoint tetanic extensor and ﬂexor isometric torque (Figure 1
and Supplemental Table S1). The major ﬂexors of the
tibiotarsal joint are the cranial tibialis, peroneus longus, and
long digital extensor (LDE). The LDE, as the name indicates,
also serves as a digital extensor. In our previous studies, we
found the LDE to be signiﬁcantly atrophied in GRMD
compared to normal dogs. Accordingly, it has been used as
a comparator for the hypertrophied CS. However, for the sake
of drawing inferences between tibiotarsal joint ﬂexion and
the molecular analysis in this study, either the cranial tibialis
or peroneus longus might have been a better choice.
Methods for measuring tibiotarsal joint angle and torque
have been described.7,8 To measure CS circumference, the
muscle was isolated at the time of surgical biopsy. Nylon
suture was placed around the muscle at approximately the
midsection and tightened to snugly encircle the muscle
belly. The two ends of the suture were secured with a pair of
hemostats and then cut on the muscle side of the hemostat.
The length in mm was divided by body weight in kg (mm/
kg). An average of two measurements was recorded.20
Muscle Biopsies
Biopsy samples from the CS, LDE, and VL muscles were
collected surgically, snap frozen in liquid nitrogenecooled
SUVA34A (a Freon analog; DuPont Fluorochemicals,
Wilmington, DE), and subsequently archived at 80C
until analysis.
RNA Extraction
Total RNA was extracted from approximately 30 mg of
ﬂash-frozen muscle using TRIzol (Invitrogen, Carlsbad,
CA). The extraction procedure was performed as recom-
mended by the manufacturer. Total RNA was stored at
80C until analysis.
mRNA Expression Proﬁling
Genome-wide mRNA analysis was performed on RNA
from the CS, LDE, and VL biopsy samples using micro-
arrays (Affymetrix Canine 2.0 GeneChip; Affymetrix, Santa
Clara, CA); 72 chips were used for the analysis [12 dogs
(N1 to N4 and D6, D11, D20, D21, D38, D40, D43, and
D49) (Supplemental Table S1), two time points, three
muscles]. Single-stranded cDNA, followed by double-
stranded cDNA, and ﬁnally biotinylated complimentary
(c)RNA were generated in a cDNA/cRNA reaction.27 Bio-
tinylated cRNA was fragmented into 50- to 200-bp seg-
ments and subsequently hybridized to the oligonucleotides
in the Canine 2.0 GeneChip. Hybridization was performed
with an Affymetrix GeneChip 640 Hybridization Oven for
16 hours at 45C (3200  g). The ﬂuorescence of hybrid-
ized biotinylated cRNA was washed and stained using the
Affymetrix GeneChip 450 Fluidics Station. Probe-set
ﬂuorescence was detected and averaged to determine the1413
Nghiem et alrelative abundance of the original mRNA by an Affymetrix
GeneChip 3000 Scanner. We focused on the CS mRNA
proﬁles for this study.
miRNA Expression Proﬁling
Genome-wide miRNA analysis was performed on total
RNA from the CS and VL samples using microarrays
(Affymetrix miRNA 3.0 GeneChip); 12 chips were used for
the analysis (12 canine samples from a total of 9 dogs: 3
GRMD CS, 3 normal CS, 3 GRMD VL, and 3 normal VL
muscles; at one time point 7.5 to 8 months). Four of these
dogs were the same that were used for mRNA proﬁling
above (N2, N4, D21, and D38), whereas ﬁve were different
(two normal dogs, Charles and Baker; and three GRMD,
Caroline, Flash, and Hagatha), not mRNA proﬁled or
included in the heat map. The FlashTag Biotin HSR RNA
Labeling Kit protocol was performed as recommended by
the manufacturer (Affymetrix). Brieﬂy, total RNA was poly-
A tailed and then ligated with biotin HSR. RNA labeling
was conﬁrmed with an enzyme-linked oligosorbent quality
control assay. Hybridization was performed with an Affy-
metrix GeneChip 640 Hybridization Oven for 16 hours at
48C (3200  g). Hybridized biotinylated miRNA was
washed and stained using the Affymetrix GeneChip 450
Fluidics Station. Probe-set ﬂuorescence was detected and
averaged to determine the relative abundance of the original
mRNA by an Affymetrix GeneChip 3000 Scanner.
Bioinformatics
The relative probe-set hybridization signal of the mRNA
proﬁles was interpreted by PLIER algorithm and visualized
using MATLAB hierarchical clustering (MathWorks,
Natick, MA). Normalization of miRNA proﬁles was per-
formed by Partek (St. Louis, MO). Ingenuity Pathway
Analysis (IPA) version 16542223 (Ingenuity Systems,
Redwood City, CA) was used to determine signiﬁcant
molecular networks within CS muscle mRNA proﬁles.
cDNA Synthesis
Generation of cDNA was performed using an Applied
Biosystems’ High Capacity cDNA Reverse Transcription
Kit (Life Technologies, Carlsbad, CA). Samples were
heated to 25C for 10 minutes followed by 37C for 2 hours
on a heating plate. qPCR reaction parameters using Applied
Biosystems Universal PCR TaqMan Master Mix (Life
Technologies) were as follows: stage 1: 50C for 2 minutes;
stage 2: 95C for 10 minutes; stage 3 repeated for 40 to 45
cycles: 95C for 15 seconds, followed by 60C for 1 minute.
qPCR
Triplicate reactions were performed with an Applied Bio-
systems 7900 HT Fast Real-Time PCR system (Life1414Technologies) for the eight arrayed GRMD dogs. MSTN
was assessed in an additional six GRMD dogs (D14, D23,
D28, D36, Athena, and Sprite). The endogenous control,
hypoxanthine guanine phosphoribosyltransferase 1 (HPRT1),
was selected due to its consistent value in all expression
proﬁles. Probes for DAG1, LARGE, MSTN, and HPRT1 were
selected from Applied Biosystems (Life Technologies) and
were used as sense/antisense primers (DAG1 assay ID:
Cf03023355_m1; LARGE assay ID: Cf02642045_m1;
HPRT1 assay ID: Cf02626258_m1; and MSTN assay ID:
Cf02704228_m1). All quantitative real-time (q)PCR results
were normalized to control samples.
Immunoﬂuorescence and Light Microscopy
Samples from the CS, LDE, and VL muscles of the eight
GRMD and four normal dogs were evaluated at 6 months
for immunoﬂuorescence of target proteins and histopatho-
logical changes. Due to the small size of the muscle biopsy
at 4 to 9 weeks, ﬁve of eight GRMD samples for the CS,
LDE, and VL were completely used during the RNA
extraction procedure, leaving samples from only three
GRMD dogs for evaluation. Frozen sections of skeletal
muscle were thawed on Superfrost Plus slides (Fisher
Scientiﬁc, Pittsburgh, PA) using a Leica Microsystems
Cryostat (Leica, Bannockburn, IL) at 25C. Immuno-
staining and H&E staining were completed on 6- to 8-mm
and 10-mm sections, respectively. Minimal Feret’s diameter
(ImageJ version 1.46r; NIH, Bethesda, MD) method was
used to measure myoﬁber diameter in H&E sections.28 The
entire ﬁeld was analyzed, and 200 to 1000 myoﬁbers per
sample were measured. The myoﬁber membrane was out-
lined and minimal Feret’s diameter calculated with ImageJ.
a-Dystroglycan mouse monoclonal IgM antibody (IIH6)
was from the Kevin P. Campbell laboratory (Iowa City,
IA). UTRN mouse monoclonal IgG antibody (MANCHO3
clone 8A4) was purchased from Developmental Studies
Hybridoma Bank (Iowa City, IA). b-Sarcoglycan mouse
monoclonal IgG antibody (B-SARC; Novocastra) was
purchased from Leica Biosystems (Buffalo Grove, IL). a-,
d-, and g-Sarcoglycan were probed with similar Novo-
castra antibodies, but no detectable cross-reaction was
visible in canine muscle. b-Spectrin 1 protein (SPTBN1;
non-erythrocytic) mouse monoclonal IgG antibody (B-
SPEC; Novocastra) was from Leica Biosystems.
ARP52859_P050 was used to probe MTPN (Aviva
Systems Biology, San Diego, CA). No detectable immu-
noreaction occurred when dog muscle was probed with a-
spectrin antibodies from Leica Biosystems. Secondary
antibodies were Cy3 conjugates from Jackson ImmunoR-
esearch Laboratories (West Grove, PA). Primary and
secondary antibodies were diluted according to the
manufacturer’s recommendations. Sections were incubated
with blocking buffer (10% horse serum and 1 PBS) for 1
hour. Sectioned samples were then incubated with the
primary antibody for 16 to 24 hours and with the secondaryajp.amjpathol.org - The American Journal of Pathology
Muscle Hypertrophy Dystrophyantibody for 1 hour. Cryosections were washed with
blocking buffer three times for 5 minutes each before and
after applying primary and secondary antibodies. Samples
were analyzed in triplicate with an Axiovert 200 M
(immunoﬂuorescence) microscope (Carl Zeiss Microscopy,
Jena, Germany) or an Olympus light microscope (light
microscopy) (Olympus, Tokyo, Japan).
Western Blot Analysis
Muscle proteins were isolated in radioimmunoprecipitation
assay buffer, proteinase inhibitor (Bio-Rad, Hercules, CA),
and phosphatase inhibitor (Roche Diagnostics, Mannheim,
Germany) and quantiﬁed with DC protein assay (Bio-Rad)
at 650 nm. Proteins (10 mg or 50 mg) were dissolved in 4
lithium dodecyl sulfate running buffer (Invitrogen) and
10 reducing agent (Invitrogen) and loaded into an SDS
NU-PAGE gel (4% to 12% Bis-Tris or 3% to 8% Tris
acetate gel) (Invitrogen) and subsequently separated via
electrophoresis at 160 V for 1 hour. Proteins were trans-
ferred to a polyvinylidene diﬂuoride membrane by a semi-
dry transfer method (Bio-Rad Trans-Blot SD Semi-Dry
Electrophoretic Transfer Cell) and incubated in blocking
buffer (5% milk in 1 Tris-buffered salineeTween) for 16
to 24 hours at 4C. The membrane was subsequently
incubated with primary antibody (dilution: 1:1000) [IIH6
for a-dystroglycan; MANCHO3 clone 8A4 for UTRN;
ARP52859_P050 for MTPN; 587F11 for phosphorylated-
AKT1 mouse monoclonal IgG antibody (587F11; Cell
Signaling Technology, Danvers, MA)] for 18 to 24 hours at
4C and horseradish peroxidaseeconjugated secondary
antibody (dilution 1:5000) for 1 hour at room temperature.
The B-SARC and B-SPEC antibodies from Leica Bio-
systems used for immunoﬂuorescence did not produce a
detectable signal for immunoblots in dog samples. Mem-
branes were washed three times for 5 minutes each with
1 Tris-buffered salineeTween after primary and
secondary antibody incubation. The membranes were
incubated with ECL Plus (GE Healthcare, Cleveland OH)
for 1 minute, then subsequently exposed to a radiographic
ﬁlm and developed. Protein gels were stained with Bio-
Safe Coomassie Blue (Bio-Rad) for 10 minutes and washed
with water overnight at 4C. Blot and gel samples were
quantiﬁed using a GS-800 Calibrated Densitometer (Bio-
Rad) with Quantity One software version 4.5.2 (Bio-Rad).
Membrane bands were normalized to myosin heavy chain
from the SDS NU-PAGE gel.
Proteomic Proﬁling
Label-free quantitative mass spectrometry was performed in
CS samples from three each GRMD and normal dogs at age
4 to 9 weeks and 6 months. These included four dogs (N1,
N3, N4, and D40) from those previously mRNA arrayed
and two that were not arrayed (D23 and D36). CS muscles
(50 10-mm sections) were cut on the cryostat and placed inThe American Journal of Pathology - ajp.amjpathol.orga microcentrifuge tube at 80C. Protein was isolated and
quantiﬁed, as detailed in Western Blot Analysis. Protein
(50 mm) was dissolved and run electrophoretically on a 4%
to 12% Bis-Tris gel (Invitrogen), and gels were stained for 1
hour. Individual protein bands were sliced and prepared for
in-gel digestion.29 Resulting peptides from each band were
analyzed using NanoLC (Eksigent, Dublin, CA) connected
to an LTQ Orbitrap XL instrument (ThermoFisher Scien-
tiﬁc, Waltham, MA) using a label-free method.30 Proteins
were identiﬁed using the SEQUEST algorithm in the Bio-
Works Browser version 3.3.1 SP1 (ThermoFisher Scientiﬁc)
against the National Center for Biotechnology Information
genome biology canine RNA database. The SEQUEST
search ﬁles were uploaded into ProteoIQ software version
2.3.07 (Nusep, Bogart, GA) for parsing and spectral
counting of two or more independent peptides mapping to
the same parent protein. Proteins were retained for further
analyses if both peptides XCorr >2.2, peptide probability
>0.98, and protein probability >0.95. Total spectra counts
for each group were used to estimate relative abundance.
Proteins of interest were identiﬁed and molecular functions
were determined based on data in Online Mendelian In-
heritance of Man (National Center for Biotechnology In-
formation, http://www.ncbi.nlm.nih.gov/omim, last accessed
March 6, 2012).Statistical Analysis
Prism software version 5.04 (GraphPad Software, La Jolla,
CA) was used for statistical testing. A correlation coefﬁcient
was used to correlate the mRNA and protein proﬁles with
CS circumference at 6 months of age. Spearman correlation
was used to test signiﬁcance between expression and
phenotype values. A nonparametric t-test was used to test
signiﬁcance between GRMD and normal dog expression
values. Paired t-test was used to test signiﬁcance of GRMD
samples between one another.Results
Associations of Phenotypic Measures in GRMD Dogs at
6 Months
The values for four phenotypic measures are provided in
Supplemental Table S1. Measures were visualized using
hierarchical clustering (heat map), where the color green
indicates a relatively lower value for each variable and red
a higher value (Figure 2). Normal dogs had larger tibiotarsal
joint angles, tetanic extensor and ﬂexor torques, and smaller
CS circumferences. The 49 GRMD dogs showed marked
variability in each measure. Mildly affected dogs had pro-
portionally larger tibiotarsal joint angles and tetanic
extensor torques and smaller CS circumferences and tetanic
ﬂexor torques. The opposite pattern was seen in severely
affected dogs (Figure 2).1415
Figure 3 Histopathological features of golden retriever muscular
dystrophy (GRMD) and normal dogs at 6 months of age, showing relative
myoﬁber hypertrophy and less pronounced acute dystrophic changes in the
cranial sartorius (CS). Cranial sartorius muscle of a normal dog (N3; A) and
a GRMD dog (D40; B). Note that the myoﬁbers are larger compared to normal
and other GRMD muscles. Endomysial connective tissue is increased, and
there are increased numbers of central nuclei. Patchy increased cellularity
associated with inﬂammation is present. Long digital extensor (LDE) muscle
of a normal dog (N4) (C) and a GRMD dog (D11) (D) illustrating myoﬁber size
variation, inﬂammatory cell inﬁltration, and increased endomysial connec-
tive tissue. Vastus lateralis (VL) muscle of a normal dog (N4) (E) and a GRMD
dog (D43) (F). F: The arrows indicate hyaline ﬁbers and associated
connective tissue, inﬂammatory cells, and small regenerating basophilic
myoﬁbers. Original magniﬁcation, 100 (AeF). Scale bars: 50 mm (AeF).
Figure 2 Heat map of unsupervised hierarchical clustering showed that
increased cranial sartorius (CS) circumference, increased ﬂexor, and
decreased extensor tetanic torque, and decreased tibiotarsal joint angle
were associated with a more severe phenotype. More severely affected dogs
had proportionally larger CS circumferences (hypertrophy), stronger tetanic
ﬂexor torques, reduced tibiotarsal joint angles (contractures), and weaker
tetanic extensor torques at 6 months. Mildly affected dogs had a reverse
pattern of involvement. The eight golden retriever muscular dystrophy (D)
and four normal (N) dogs selected for histopathological and molecular
analyses are identiﬁed with black areas: golden retriever muscular
dystrophy dogs (left to right): D6, D11, D20, D21, D38, D40, D43, and D49;
normal (W/T) dogs (left to right): N1, N2, N3, and N4. Red, increased;
green, decreased.
Nghiem et alMyoﬁber Hypertrophy Is Seen in the GRMD CS Muscle at
6 Months
Histopathological changes in eight GRMD dogs with mild-
to-severe phenotypes were contrasted with one another and
four age-matched normal controls (see Figure 2 for dogs
selected). Three muscles (CS, VL, and LDE) were assessed
in three of the eight GRMD dogs at 4 to 9 weeks and in all
eight at 6 months of age. Muscles in the four normal dogs
were assessed at both ages. Muscles from age-matched
controls were histologically normal (Figure 3, A, C, and
E). All GRMD muscles had lesions of necrotizing myop-
athy. These changes varied depending on the age and
muscle. At 4 to 9 weeks, each of the GRMD muscles had
multifocal clusters of necrotic myoﬁbers, mononuclear cell
inﬂammation, expansion of the perimysial and endomysial
spaces, and groups of small, basophilic regenerating myo-
ﬁbers. Changes were generally more pronounced in the CS
compared to the VL or LDE at this younger age. By 6
months, lesions of active necrosis had largely resolved in the
CS (Figure 3B), whereas the VL and LDE still showed
small group myoﬁber necrosis and regeneration (Figure 3, D
and F). The minimal Feret’s diameter (means  SD) of
GRMD CS myoﬁbers at 4 to 9 weeks (14.7  5.1 mm) and 6
months (61.1  16.7 mm) was larger relative to those from
age-matched normal littermates (9.3  3 mm at 4 to 9
weeks; P < 0.05; and 36.7  6.2 mm at 6 months; P <
0.001), as well as the GRMD LDE (10  3.0 mm at 4 to 9
weeks; P Z 0.06; and 41.4  18.3 mm at 6 months; P <14160.01) and VL (7.6  2.0 mm at 4 to 9 weeks; P < 0.05; and
39.7  13.5 mm at 6 months; P < 0.01) muscles (Figure 4,
A and B). These data indicate that GRMD CS hypertrophy
begins as early as age 4 to 9 weeks when dogs are relatively
mildly affected.
MSTN Is Associated with CS Muscle Hypertrophy
Because MSTN expression is strongly correlated with
muscle size,24,25 we hypothesized that levels would be
decreased in the hypertrophied CS muscle. The CS and VL,
but not the LDE, showed strong age-related decreased
MSTN mRNA expression. MSTN expression was most
profoundly decreased in the hypertrophied CS at 6 months
of age (average fold change Z 25; P < 0.05; n Z 8)
(Figure 4C), at which time there was also an inverse
correlation between qPCR levels and CS muscle circum-
ference (r Z 0.73; r2 Z 0.53; P < 0.05; n Z 8)
(Figure 4D). We conﬁrmed the size-related decrease in
MSTN (average fold change Z 6.5 compared to normal)
in the CS and VL muscles compared to normal controls with
qPCR in six additional GRMD dogs, four of which were
included in the heat map (Athena, Sprite, D14, D23, D28,
and D36; not shown).ajp.amjpathol.org - The American Journal of Pathology
Figure 5 Regulators of myostatin are increased in the hypertrophied
golden retriever muscular dystrophy (GRMD) cranial sartorius (CS) muscle.
Figure 4 Myoﬁber hypertrophy in golden retriever muscular dystrophy
(GRMD) cranial sartorius (CS) and myostatin (MSTN) expression is inversely
correlated with bodyweight-corrected CS circumference (mm/kg). A: Myo-
ﬁber diameter is increased in GRMD (D) CS at 4 to 9 weeks compared to
normal (N) and GRMD vastus lateralis (VL). GRMD CS tend to be greater than
long digital extensor (LDE; P Z 0.06). GRMD LDE and VL are not signiﬁ-
cantly different from respective normal samples. B: Myoﬁber diameter is
increased in GRMD CS at 6 months compared to normal, GRMD LDE, and
GRMD VL. GRMD LDE and VL are not signiﬁcantly different from respective
normal samples. C: MSTN qPCR expression revealed decreased expression in
GRMD muscle, with the greatest decrease in the hypertrophied CS at 6
months (6M; nZ 8 arrayed dogs). D: MSTN mRNA was inversely correlated
with CS size at 6 months in the CS of GRMD dogs of the discovery data set
(rZ 0.73; r2Z 0.53; P < 0.05; nZ 8 arrayed dogs). *P < 0.05, **P <
0.01, and ***P < 0.001.
Muscle Hypertrophy DystrophymiRNAs that Modulate MSTN Are Up-Regulated in the
Hypertrophied CS
We were intrigued by this differential expression of MSTN
in GRMD CS compared to the other dystrophic muscles
and sought to deﬁne possible upstream modulators of
MSTN. MSTN has a highly conserved 30euntranslated
region with multiple miRNA binding sites. We hypothe-
sized that altered regulation of miRNAs could account for
the observed differential expression of MSTN in GRMD
muscle. Using Affymetrix GeneChip 3.0 miRNA proﬁles,
we found increased target miRNAs predicted to regulate
MSTN in the hypertrophied GRMD [miR-539 (fold changeZ
þ3; P < 0.05) and miR-208b (fold change Z þ2; P <
0.05)]. Moreover, GRMD CS showed greater increases in
miR-539 and miR-208b compared to normal CS and VL
and GRMD VL samples (Figure 5, A and B). These data
suggest that differential regulation of upstream miRNAs
targeting MSTN contributes to CS muscle hypertrophy.A: cfa-miR-208b_st was increased in GRMD (D) CS compared to normal (N)
CS (fold change Z þ2). B: cfa-miR-539_st was increased in GRMD CS
compared to normal CS (fold change Z þ3). C: AKT1 phosphorylation at
serine 473 was increased in GRMD and positively correlated with CS
circumference at 6 months (rZ þ0.78; r2Z 0.6; P < 0.05; nZ 8). miRNA
proﬁling was used to detect target miRNAs. Western blot and densitometry
was used to detect AKT1 phosphorylation status. Numbers to the left of the
membranes and gels indicate molecular weight (kDa). MHC, myosin heavy
chain. *P < 0.05AKT1 Phosphorylation Is Associated with Increased
Muscle Size in the Hypertrophied CS in GRMD Dogs at
6 Months
MSTN has been shown to regulate muscle growth, at least in
part, through regulation of AKT1. Inhibition of MSTN leadsThe American Journal of Pathology - ajp.amjpathol.orgto an increase in myotube diameter and Akt phosphoryla-
tion.31 To query differential AKT1 phosphorylation status
as an additional regulator of MSTN, we deﬁned the phos-
phorylation status of AKT1 in the different muscles in the
dogs by Western blot. AKT1 phosphorylation (normalized
to myosin heavy chain) was increased in the hypertrophied
CS muscle (Figure 5C) and positively correlated with CS
circumference at 6 months (rZ þ0.78; r2Z 0.6; P < 0.05;
n Z 7) (Figure 5C). AKT1 phosphorylation remained
unchanged between normal and GRMD LDE samples (data
not shown), suggesting that the MSTN/AKT1 pathway
changes were speciﬁc to the hypertrophied CS muscles.
Thus, two regulators of MSTN, miRNAs and AKT1 phos-
phorylation status, are consistent with active down-regulation
of MSTN in the CS. The resulting hypertrophy illustrates a
muscle-speciﬁc response to dystrophin deﬁciency.UTRN Increases in GRMD Muscles But Is Not Speciﬁc to
the CS and Does Not Correlate with CS Size
We hypothesized that the autosomal homologue of dystro-
phin, UTRN, would be increased at the myoﬁber membrane
of GRMD CS and that its expression would correlate with
CS hypertrophy. Immunoﬂuorescent UTRN expression was
faint with microscopy, but more pronounced in all three
GRMD versus normal muscles at both time points (not
shown). On Western blots, UTRN was also increased in
each of the three GRMD muscles (CS, 190%; LDE, 167%;
and VL, 197% of normal levels) at 6 months (Figure 6).1417
Figure 6 Western blot shows increased utrophin (UTRN) expression in
golden retriever muscular dystrophy (GRMD) cranial sartorius (CS) muscle at
6 months. In GRMD (D) CS, UTRN was expressed at 190% of the level of
normal dogs (N) at 6 months. Levels in the long digital extensor and vastus
lateralis were at 167% and 197%, respectively, of age-matched normal
samples (not shown). Numbers to the left of the membranes and gels
indicate molecular weight (kDa). MHC, myosin heavy chain.
Figure 7 DAG1 and LARGE are in the top-ranked network associated
with cranial sartorius hypertrophy. Transcripts associated with cranial
sartorius size (n Z 250) were entered into ingenuity pathway analysis
(IPA), and ranked networks were generated. We focused on DAG1 and LARGE
(black arrows) in the top-ranked network (shown) due to their association
with the dystrophin-glycoprotein complex.
Nghiem et alHowever, UTRN protein expression was not signiﬁcantly
correlated with CS size in GRMD dogs (data not shown).
Novel Molecular Networks Are Quantitatively
Associated with Variable CS Muscle Hypertrophy
We sought to ﬁnd novel molecular signatures associated with
muscle hypertrophy in response to dystrophin deﬁciency.
mRNA microarray proﬁles were performed on the CS, LDE,
and VL muscles from eight GRMD dogs and four normal
dogs from the heat map at both 4 to 9 weeks and 6 months.
Using quantitative trait analyses, we queried for mRNAs that
were strongly correlated with the degree of CS hypertrophy at
6 months, using a rigorous threshold for correlation coefﬁ-
cients (r  0.94; r2  0.88) and stringent P values asso-
ciated with those r values (P  0.001). Two hundred ﬁfty
transcripts met these correlation coefﬁcient and P value
criteria, and were studied further (Supplemental Table S2).
The 250 transcripts that were associated with CS hyper-
trophy were entered into IPA software to determine the most
signiﬁcant molecular networks associated with muscle
hypertrophy. The top-ranked pathway included genes cod-
ing for two dystrophin-associated mRNAs, namely DAG1
(highest correlation with CS hypertrophy; P Z 0.00009;
r Z 0.98) and LARGE enzyme responsible for O-linked
glycosylation of DAG1 (fourth lowest correlated transcript;
P Z 0.001; r Z 0.94) (Figure 7).32 We have previously
shown that levels of the protein product of DAG1, a-dys-
troglycan, in the GRMD peroneus longus muscle correlate
with contraction tension and CK levels, suggesting that it
could play a role in stabilizing the myoﬁber membrane.331418We chose to focus on validation of these two transcripts
due to our previous results and their close relationship with
the dystrophineglycoprotein complex. A brief description
of the other transcripts in the highest-ranked IPA network
from Figure 7 can be found in Supplemental Table S3.
DAG1 and LARGE mRNAs Are Up-Regulated in all
Dystrophic Muscles
To determine whether increased DAG1 and LARGE mRNAs
were speciﬁc to the hypertrophied CS, we queried the probe
sets for these candidates in all 72 microarrays and also
performed qPCR to validate the microarray ﬁndings. This
analysis showed that the DAG1 and LARGE mRNAs were
most up-regulated in CS at both 4 to 9 weeks and 6 months
of age (Table 1). DAG1 and LARGE qPCR expression
values correlated directly with CS circumference at 6months
(Supplemental Figure S2), validating the microarray data.
Also similar to the microarray data, qPCR analysis of all 72
GRMDmuscles forDAG1 and LARGE showed up-regulation
compared to normal, but reached signiﬁcance only for DAG1
mRNA in GRMD CS at 6 months (P 0.05) and the VL at 4
to 9 weeks (P  0.05) (Table 1).
Glycosylated a-Dystroglycan Protein Decreases in
GRMD Muscles Compared to Normal But Proportionally
Greater in the GRMD CS
Glycosylated a-dystroglycan protein was markedly reduced
compared to normal but present on immunostaining in allajp.amjpathol.org - The American Journal of Pathology
Table 1 Array and qPCR Values for DAG1 and LARGE in GRMD and Normal Muscle
Transcript Muscle
Normal array GRMD array GRMD qPCR
4e9 weeks 6 months 4e9 weeks 6 months 4e9 weeks 6 months
DAG1 CS 439  51 (3) 220  28 (3)* 664  93 (8) 562  51 (8)* þ1.3  0.21 (8) þ1.6  0.11 (8)*
DAG1 LDE 522  59 (4) 370  29 (4) 459  43 (8)yz 418  42 (8)yz þ1.27  0.1 (8) þ1.27  0.18 (8)
DAG1 VL 548  84 (4) 355  51 (4) 643  40 (8)z 417  37 (8)z þ1.7  0.28 (8) þ1.8  0.47 (8)
LARGE CS 146  19 (4) 120  11 (4) 121  6 (8)yz 198  20 (8)yz þ1.4  0.22 (8) þ1.4  0.15 (8)
LARGE LDE 72  10 (4) 107  4 (4) 87  8 (8)yz 100  3 (8)yz þ1  0.09 (8)z þ1.29  0.25 (8)z
LARGE VL 98  9 (4) 109  11 (4)* 105  6 (8) 131  12 (8)* þ1.4  0.09 (8)*x þ1.7  0.36 (8)
Array values are reported as expression units. qPCR values are reported as fold change relative to normal. All values are means  SEM (n).
*P < 0.05 versus age/muscle-matched normal.
yP < 0.05 versus age (4 to 9 weeks versus 6 months) within the same disease (normal or GRMD) and muscle (CS, LDE, or VL) group.
zP < 0.05 versus muscle (CS versus LDE or VL) within the same genotype (normal or GRMD) and age (4 to 9 weeks or 6 months) group.
xP < 0.05 versus muscle (LDE versus VL) within same genotype (normal or GRMD) and age (4 to 9 weeks or 6 months) group.
Muscle Hypertrophy DystrophyGRMD muscles at both ages. a-Dystroglycan expression
was most pronounced in the CS at 6 months (Figure 8B),
where immunoblot levels were at 33% of normal (not
shown). The degree of expression did not correlate with the
degree of CS hypertrophy, although this analysis was highly
subjective. Despite multiple attempts, we could not produce
interpretable immunoblots for glycosylated a-dystroglycan
protein in the LDE and VL muscles. By comparison,
b-sarcoglycan protein immunostaining in myoﬁbers was
uniform in normal dogs (Figure 8D) but reduced and patchyThe American Journal of Pathology - ajp.amjpathol.orgamong the three GRMD muscles, regardless of age
(Figure 8, E and F).
Spectrin Increases in Hypertrophied CS Muscles of
GRMD Dogs
Both a- and b-spectrin spectral counts were increased on
proteomic proﬁling (mass spectrometry) in GRMD CS
compared to normal at 4 to 9 weeks and 6 months (Table 2).
By immunostaining, b-spectrin was uniformly expressed atFigure 8 Immunoﬂuorescence microscopy of
a-dystroglycan (DAG1), b-sarcoglycan (SGCB), and
b-spectrin (SPTBN1) reveals variable expression in
golden retriever muscular dystrophy (GRMD)
muscles at 6 months. A: In normal muscle, DAG1 is
expressed at the membrane in every myoﬁber
observed. B and C: DAG1 is variably expressed at
the membrane in GRMD cranial sartorius (CS; B),
long digital extensor (LDE), and vastus lateralis
(VL) muscles (C), but appears to have greater
intensity in the CS. D: SGCB is expressed at the
membrane of every myoﬁber in normal dogs. E and
F: In GRMD dogs, SGCB is expressed at the
membrane of myoﬁbers in the CS (E), LDE, and VL
(F), but less than normal samples. No differences
in intensity are seen among the three GRMD
muscles. G: SPTBN1 is expressed at the myoﬁber
membrane in all normal muscles. H and I: The
intensity of expression in the GRMD CS (H) is
greater than normal and other affected muscles
(I). J: Myotrophin (MTPN) is expressed in the
perimembranous region of myoﬁbers in normal
muscle. K: GRMD CS muscle shows perimembranous
staining. L: GRMD VL samples at 6 months showed
slightly increased perimembranous myoﬁber MTPN.
Original magniﬁcation, 100 (AeL). Scale bars:
50 mm (AeL).
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Table 2 Total Spectral Counts for Spectrin, Myotrophin, and
Laminin-a2 from Proteomic Proﬁling Results
Genotype Age SPTAN1 SPTBN1 MTPN LAMA2
Normal 4e9 weeks 43 7 7 54
6 months 36 1 5 3
GRMD 4e9 weeks 65 19 12 12
6 months 65 3 15 0
Sum of spectral counts for each group is shown. There are nZ 3 proﬁles
for normal and GRMD at 4 to 9 weeks and at 6 months (12 total proﬁles).
LAMA2, laminin-a2; MTPN, myotrophin; SPTAN1, a-spectrin; SPTBN1,
b-spectrin.
Figure 9 Myotrophin (MTPN) is increased on immunoblots of the
cranial sartorius (CS) at 4 to 9 weeks and 6 months in golden retriever
muscular dystrophy (GRMD) dogs. A: MTPN is increased on immunoblots of
GRMD (D) CS muscles assessed by proteomics. B: MTPN is increased in GRMD
CS muscles on immunoblots of arrayed dogs, but not expressed in normal
(N) samples or GRMD long digital extensor (LDE) or vastus lateralis (VL)
muscles. Numbers to the left of the membranes and gels indicate molecular
weight (kDa). MHC, myosin heavy chain.
Nghiem et althe myoﬁber membrane in both normal (Figure 8G) and
GRMD muscles, with greater intensity in the CS (Figure 8H)
compared to other GRMD muscles (Figure 8I). By contrast,
laminin-a2 protein expression, as detected by proteomic
proﬁling, was reduced at 4 to 9 weeks and absent at 6 months
(Table 2). However, immunostaining of laminin-a2 in
normal and GRMD muscle samples showed strong and
similar staining, suggesting that the reductions seen by pro-
teomics were due to lack of sensitivity of this technique (data
not shown).
Myotrophin Increases in Hypertrophied CS But Not in
Other Muscles
In assessing proteomic proﬁling data for other growth
factors that could contribute to CS hypertrophy, we were
struck by increased total spectral counts for MTPN at both 4
to 9 weeks and 6 months (Table 2). Levels of MTPN were
also increased on immunoblot analysis at 4 to 9 weeks and 6
months in the CS GRMD samples proﬁled with both pro-
teomics (Figure 9A) and mRNA microarrays (Figure 9B).
No immunoblot signal for MTPN was seen in normal or
GRMD LDE or VL muscles (Figure 9B). There was faint
perimembranous, but no cytoplasmic, myoﬁber staining for
MTPN, in all three muscles of both normal and GRMD dogs
(Figure 8, J and L). Additional perimembranous staining of
MTPN was also seen in small GRMD myoﬁbers at 4 to 9
weeks and hypertrophied ﬁbers at 6 months, consistent with
a unique expression pattern (Figure 8K).
Discussion
Mechanisms responsible for relative sparing or hypertrophy
of dystrophin-deﬁcient muscles are poorly deﬁned. The
GRMD CS muscle, which undergoes early necrosis followed
by remarkable hypertrophy,9,19 provides a platform on which
factors contributing to hypertrophy can be explored. Studies
reported here tested the hypothesis that speciﬁc age-related
molecular signatures support growth and hypertrophy of
this muscle. To identify a cohort of GRMD dogs to be in-
cluded in molecular studies, unsupervised hierarchical clus-
tering of functional outcome measures was ﬁrst completed
in 49 6-month-old GRMD dogs. Consistent with our earlier1420studies,19,34,35 there was dramatic phenotypic variation.
Mildly affected dogs had proportionally smaller CS muscles,
lower tetanic ﬂexor torque, and larger tibiotarsal joint angles
and tetanic extensor torque. The opposite pattern was seen
in severely affected dogs. Variably affected GRMD dogs
from the larger cohort were assessed at the mRNA and
protein level to identify molecular ﬁngerprints that could
explain differential muscle involvement, speciﬁcally CS
hypertrophy.
In keeping with previous studies,9,19,20 histopathological
analysis of GRMD muscles showed lesions of necrotizing
myopathy that varied depending on the age and muscle.
Changes were generally more pronounced in the CS
compared to the VL or LDE at the younger (4 to 9 week)
age. There was expansion of the perimysial and endomysial
spaces in all muscles at both time points. Lesions of active
necrosis had largely resolved in the CS at 6 months, whereas
the VL and LDE still showed small group myoﬁber necrosis
and regeneration. We had previously shown that the mean
lesser (Feret’s) diameter of CS myoﬁbers is normal at 4
weeks19 but increased at 6 months.9 This work was
extended by measurement of myoﬁber diameter in all three
muscles at 4 to 9 weeks and 6 months in the dogs in this
study. CS myoﬁber diameter was increased at both ages,
suggesting that molecular players are involved early in
muscle hypertrophy.
We were particularly interested in factors that were either
involved in regulation of muscle mass or could potentially
serve as dystrophin surrogates to stabilize the myoﬁber
membrane. Studies initially focused on MSTN because of
its well-established role as a potent negative growth regu-
lator of skeletal muscle mass.24,25 As reported previously in
DMD36 and the mdx mouse,37 we hypothesized that MSTN
would be decreased in GRMD muscle proportional to the
degree of hypertrophy. This hypothesis was supported by
results of qPCR, because MSTN levels in GRMD muscles,
and especially the hypertrophied CS at 6 months, were
lower than normal. Moreover, MSTN levels correlated
inversely with CS circumference at 6 months, in keepingajp.amjpathol.org - The American Journal of Pathology
Muscle Hypertrophy Dystrophywith an active role in muscle hypertrophy. Although our
prior studies and the myoﬁber measurements made here
suggest that the CS undergoes true hypertrophy, connective
tissue is increased at 6 months and even more so at later
ages.9 Previous studies have shown that MSTN can increase
myoﬁbroblast proliferation and inhibition of MSTN
decreases ﬁbrosis in dystrophic muscle.38 Interestingly,
although GRMD MSTN mRNA decreased proportionally to
normal levels in the CS and VL at the two ages studied,
levels in the LDE were stable, perhaps contributing to the
severe wasting that has been documented in this muscle.9
To determine the molecular pathways mediating the
differential expression of MSTN, we performed studies of
miRNAs targeting MSTN mRNA 30euntranslated region
and AKT1 phosphorylation status. miRNA proﬁling of two
miRNAs, miR-208b and miR-539, predicted to down-
regulate MSTN, showed two to three times higher levels
in GRMD CS relative to normal CS and VL or GRMD VL,
consistent with a role of these miRNAs in MSTN down-
regulation and associated CS hypertrophy. The serine thre-
onine kinase AKT1 was also assessed. It has previously
been shown that MSTN knockout leads to increased phos-
phorylation at AKT serine 473 and myotube hypertrophy.31
Therefore, we hypothesized that AKT1 could mediate
hypertrophy in CS muscle. AKT1 phosphorylation on
Western blot analysis correlated with CS muscle size in
GRMD dogs at 6 months, suggesting a relationship between
AKT1 and muscle hypertrophy. By contrast, a previous
study showed that AKT1 and AKT2 knockout mice, in which
MSTN was blocked with an activin receptor IIB fusion
protein, still had increased muscle growth and function.39
These results suggested that AKT1 is not essential for
activin receptor IIBemediated inhibition of muscle size and
function.39 On the contrary, our data showed a strong
correlation between AKT phosphorylation and GRMD CS
muscle size. Consistent with these results, AKT1 phos-
phorylation status in the LDE muscle, which atrophies to
one-half normal size in GRMD, did not differ in GRMD and
normal samples. Our data suggest that AKT1 and MSTN are
important myogenic factors, along with others, responsible
for muscle-speciﬁc responses to dystrophin deﬁciency, such
as CS hypertrophy.
Without the dystrophineglycoprotein complex, the myo-
ﬁber membrane is subject to tears, allowing entry of calcium,
activation of proteases, and subsequent cell necrosis. Dys-
trophin homologs and other proteins could potentially
stabilize the myoﬁber membrane in the absence of dystro-
phin. Although dystrophin was predictably uniformly absent
on immunoblotting and immunoﬂuorescence microscopy in
all GRMD samples at both ages, the autosomal protein,
UTRN, was increased. This was consistent with other studies
showing that overexpression of UTRN ameliorated the
dystrophic process in mdxmice40 and GRMD dogs.41 A lack
of UTRN up-regulation was also offered as a potential
explanation for the more severe cardiac phenotype in GRMD
versus the mdx mouse.42 However, because UTRN wasThe American Journal of Pathology - ajp.amjpathol.orgincreased in all GRMD muscles studied here, and CS levels
did not correlate with size at 6 months, it did not appear to
play a speciﬁc role supporting hypertrophy.
To determine novel molecular pathways that could drive
muscle hypertrophy or stabilize the muscle cell membrane,
mRNA was analyzed in the GRMD CS muscle. We
hypothesized that transcripts correlating with CS hyper-
trophy (r > 0.9, P < 0.001, n Z 250 transcripts) could be
involved in muscle hypertrophy. The top-ranked network in
the IPA that correlated with CS muscle hypertrophy
included two genes that encode DAG1 and its glycosyl-
transferase, LARGE, of particular interest because of their
close relationship with dystrophin and associated membrane
proteins. The DAG1 mRNA codes for a single propeptide
that is subsequently cleaved to form a and b protein
subunits. a-Dystroglycan is extracellular and binds to mer-
osin a-2 laminin in the basement membrane, whereas
b-dystroglycan is a transmembrane protein and binds to
dystrophin. In the absence of dystrophin, the dystroglycans
and other proteins of the dystrophineglycoprotein complex
should be decreased by up to 80% to 90% in dystrophic
muscle.43,44 Indeed, we have previously shown that a-dys-
troglycan protein levels are reduced by approximately 75%
in the GRMD peroneus longus muscle.33 However, this
same study suggested that a-dystroglycan expression could
stabilize the dystrophic membrane in that levels correlated
with both contraction tension and CK values. Consistent
with this ﬁnding, levels of DAG1 and LARGE mRNA both
correlated with CS hypertrophy at 6 months of age, leading
us to hypothesize that the protein product, a-dystroglycan,
would be increased as well. Thereby, just as apparently
occurs with the GRMD peroneus longus,33 a-dystroglycan
could substitute for dystrophin, playing a role hypothesized
for UTRN and other membrane-associated proteins, such as
spectrin.45 To conﬁrm this hypothesis, it was critical to
demonstrate that a-dystroglycan had actually been trans-
lated from the mRNA; alternatively, the array data could
just reﬂect a positive feedback loop whereby mRNA
levels were increased subsequent to loss of the respective
protein as the membrane underwent necrosis. Immuno-
ﬂuorescence microscopy and immunoblotting revealed a-
dystroglycan expression in GRMD muscles, with 6-month
levels being higher in the CS muscle at 33% normal.
Unlike our mRNA ﬁndings, levels did not appear to
correlate with CS circumference.
Another study found that overexpression of GalNAc
transferase increased glycosylated a-dystroglycan at the
myoﬁber membrane and lessened dystrophic lesions in mdx
mice.46 In keeping with LARGE playing an active role
in muscle hypertrophy, mRNA levels in the GRMD CS at
6 months were higher than those for normal CS or other
GRMD muscles at this same age. Although these data
suggest that LARGE may facilitate CS hypertrophy, further
studies are needed to determine whether LARGE actually
enhances glycosylation of a-dystroglycan in the GRMD
CS muscle. A separate paper found that increased a- and1421
Nghiem et alb-dystroglycan in transgenic mdx mice did not ameliorate
dystrophic lesions.47 But these mice also had less UTRN
expression, leading the authors to suggest the transgenic
dystroglycan isoform differed from the one binding UTRN
at the myoﬁber membrane.47 Along these same lines, dys-
troglycan typically colocalizes with the sarcoglycan
complex at the myoﬁber membrane, and its expression often
parallels that of sarcoglycan. Similar to what occurs with a-
dystroglycan, we found decreased but persisting expression
of b-sarcoglycan in all GRMD versus normal muscles.
Interestingly, mdx mice expressing sarcoglycans, including
b-sarcoglycan, lived longer and had an improved phenotype
compared to the double-mutant sarcoglycan/mdx mouse.48
Therefore, persisting expression of b-sarcoglycan in the
GRMD dogs of this study could provide an analogous
protective function.
Proteomic proﬁling via mass spectrometry was performed
to identify other novel growth factors and dystrophin-
associated proteins that could contribute to CS hyper-
trophy. Although the analysis was hindered by the lack of
a mature protein database for dogs, we followed up on target
proteins of interest. We chose to focus on MTPN, a 12-kDa
growth factor that is expressed in small, regenerating
myoﬁbers of DMD,49 mdx skeletal muscle,49 and GRMD
VL muscle.50 In the proﬁled dogs, MTPN was up-regulated
in the CS at 4 to 9 weeks and even more so at 6 months. The
speciﬁcity of such a response was not supported by another
study showing increased MTPN on proteomic proﬁles of the
VL muscle from 4-month-old GRMD dogs.50 This may be
due to the increased sensitivity of mass spectrometry of VL
samples performed in the previous study50 compared to
Western blot of VL samples in our study.
On a similar note, we wanted to assess other proteins that
could help support the cytoskeleton and membrane, and
queried members of the dystrophineglycoprotein complex
in the proteomic proﬁles. Similar to the immunoblot and
immunoﬂuorescence studies, dystrophin was absent from
GRMD dogs (not shown). Laminin-a2 protein expression
might logically have been expected in the hypertrophied CS
muscle, but levels were reduced at 4 to 9 weeks and absent
at 6 months, consistent with disruption of the overall
complex. Our failure to detect laminin may have occurred
because of limitations of the LTQ Orbitrap XL instrument to
detect low peptide levels. This was supported by the
detection of laminin expression in the basal lamina of nor-
mal and GRMD samples by immunostaining (not shown).
In addition, a-dystroglycan and laminin-a2 showed reduc-
tions in GRMD muscles by mass spectrometry, but
these were likely due to lack of sensitivity of proteomic
proﬁling for large, highly glycosylated proteins.51 We found
increased levels of the a and b chains of spectrin in GRMD
CS at 6 months and even more so at 4 to 9 weeks compared
to normal. The higher levels at 4 to 9 weeks may have
occurred because of the predominance of smaller myoﬁbers
at this age, with an associated increased membrane surface
area. Immunostaining for b-spectrin was also identiﬁed in1422GRMD CS at 6 months, seemingly with greater intensity
than the other dystrophic muscles, consistent with a role in
membrane stabilization necessary for growth. Although
these ﬁndings are intriguing, another recent study did not
ﬁnd differential spectrin expression in human dystrophic
muscle and recommended its use as an internal control for
dystrophin immunoﬂuorescence.52 The differences in b-
spectrin expression may have been due to the amount of
hypertrophy seen in the CS in this study compared to the
typical atrophy seen in DMD samples.52
The differential involvement of tibiotarsal joint ﬂexors
and extensors, as reﬂected by their force values, was dis-
cussed in a prior paper.8 Although this method does not
directly assess function of the CS or VL muscles, ﬂexor and
extensor muscles tend to show similar patterns of disease.
This is well represented by the analogous changes seen in a-
dystroglycan levels of the GRMD peroneus longus33 and
those of the CS reported here. Findings from the LDE must
be interpreted in the context of its dual function as a tarsal
(ankle) ﬂexor and digital extensor. Despite an increase
in ﬂexor torque in GRMD dogs at 6 months, the LDE
undergoes atrophy/wasting.9 Thus, changes in the LDE
likely do not reﬂect the molecular basis for increased tarsal
ﬂexor force. We also saw differential expression patterns of
the targeted genes/proteins (MSTN, a-dystroglycan, spec-
trin, and MTPN) between the CS and LDE muscles. Taken
together, our results suggest that multiple factors contribute
to CS hypertrophy in GRMD dogs. Perhaps, most impor-
tantly, the potent negative growth regulator MSTN was
down-regulated and inversely correlated with CS circum-
ference at 6 months of age. Moreover, increases of the
growth factor, MTPN, were speciﬁc to the hypertrophied
CS, perhaps providing another pathway for hypertrophy.
We were also intrigued by dystrophin surrogates that could
stabilize the muscle cell membrane. Although DAG1 and
LARGE mRNAs and a-dystroglycan, b-sarcoglycan, and
UTRN proteins were all proportionally increased in the
GRMD CS, they were also variably expressed in the LDE
and VL samples, even though these muscles typically
atrophy. Early necrosis in the CS versus the more delayed
onset of lesions in the VL and LDE may lead to different
patterns of disease. We believe that the convergence of
factors driving both differentiation and regeneration in
muscles that undergo early necrosis can lead to a disordered
response and selective hypertrophy. Coincident or subse-
quent up-regulation of additional dystrophin-associated
proteins, including b-dystroglycan, sarcospan, syntrophins,
and other sarcoglycans, could further stabilize myoﬁber
membranes in dystrophin-deﬁcient individuals and should
be evaluated in GRMD.
mRNA, miRNA, and proteomic data were evaluated at
4 to 9 weeks and 6 months of age to take advantage of
available functional data for correlation at 6 months. Due to
a small number of samples left for histopathological/
morphometric and molecular analyses, we could not fully
correlate 4- to 9-week data with functional measures at 6ajp.amjpathol.org - The American Journal of Pathology
Muscle Hypertrophy Dystrophymonths. Given that necrosis occurs in the GRMD CS
muscle within the ﬁrst few days of life, it might be necessary
to evaluate molecular data at even earlier time points to gain
a full understanding of factors that drive muscle hyper-
trophy. This work should ideally be expanded to determine
whether these proteins could be manipulated for therapeutic
beneﬁt. As an example, delivery of antisense oligonucleo-
tides to inhibit the respective mRNA at a young age, with
subsequent histopathological, morphometric, and molecular
analysis of the CS muscle at 6 months, might elucidate
underlying mechanisms. In addition, adeno-associated virus
vector delivery of respective genes to the CS muscle of
young GRMD dogs should be considered.
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